Design of coltuximab ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: Structure-activity relationships and preclinical evaluation

Molecular Pharmaceutics

Volumn 12, Issue 6, 2015, Pages 1703-1716

  Hong, E Erica ^a   Erickson, Hans ^a,c   Lutz, Robert J ^a   Whiteman, Kathleen R ^a   Jones, Gregory ^a   Kovtun, Yelena ^a   Blanc, Veronique ^b   Lambert, John M ^a  

^a IMMUNOGEN INC   (United States)

^b SANOFI   (France)

^c GENENTECH INC   (United States)

Author keywords

ADC; antibody drug conjugate; B cell lymphoma; CD19; coltuximab ravtansine; DM4; immunoconjugate; maytansine; SAR3419

Indexed keywords

ANTIBODY CONJUGATE; CD19 ANTIGEN; COLTUXIMAB RAVTANSINE; DRUG METABOLITE; MAYTANSINE; METHYLTRANSFERASE; N2 DEACETYL N2 [4 MERCAPTO 4 METHYL 1 OXOPENTYL]MAYTANSINE; SULFONE DERIVATIVE; SULFOXIDE; THIOL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CATABOLISM; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HL 60 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYSOSOME; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE CHECKPOINT; CELL CYCLE G2 PHASE; CELL DIVISION; CHEMISTRY; DRUG EFFECTS; LIVER; LYMPHOMA; METABOLISM; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; G2 PHASE; HUMANS; LIVER; LYMPHOMA; MAYTANSINE; MICE; MICE, SCID; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930639143     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00175     Document Type: Article

References (46)

1. Jemal, A. Cancer statistics, 2008 CA Cancer J. Clin. 2008, 58 (2) 71-96
2. McLaughlin, P. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J. Clin. Oncol. 1998, 16 (8) 2825-33
3. Coiffier, B. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 1998, 92 (6) 1927-32
4. Coiffier, B. Effective immunochemotherapy for aggressive non-Hodgkins lymphoma Semin. Oncol. 2004, 31 (1 Suppl. 2) 7-11
5. Czuczman, M. S. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J. Clin. Oncol. 1999, 17 (1) 268-76
6. von Mehren, M.; Adams, G. P.; Weiner, L. M. Monoclonal antibody therapy for cancer Annu. Rev. Med. 2003, 54343-69
7. Davis, T. A.; Czerwinski, D. K.; Levy, R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin. Cancer Res. 1999, 5 (3) 611-5
8. Kennedy, G. A. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkins lymphoma: a retrospective review Br. J. Haematol. 2002, 119 (2) 412-6
9. Tedder, T. F.; Inaoki, M.; Sato, S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity Immunity 1997, 6 (2) 107-18
10. Scheuermann, R. H.; Racila, E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy Leuk. Lymphoma 1995, 18 (5-6) 385-97
11. Anderson, K. C. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood 1984, 63 (6) 1424-33
12. Nadler, L. M. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes J. Immunol. 1983, 131 (1) 244-50
13. Nadler, L. M. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation J. Clin. Invest. 1984, 74 (2) 332-40
14. Grossbard, M. L. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms J. Clin. Oncol. 1993, 11 (4) 726-37
15. Grossbard, M. L. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkins lymphoma Clin. Cancer Res. 1999, 5 (9) 2392-8
16. Furman, R. R. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254 Leuk. Lymphoma 2011, 52 (4) 587-96
17. Polson, A. G. Antibody-drug conjugates for the treatment of non-Hodgkins lymphoma: target and linker-drug selection Cancer Res. 2009, 69 (6) 2358-64
18. Gerber, H. P. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas Blood 2009, 113 (18) 4352-61
19. Herbst, R. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody J. Pharmacol. Exp. Ther. 2010, 335 (1) 213-22
20. Horton, H. M. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia Cancer Res. 2008, 68 (19) 8049-57
21. Nagorsen, D.; Baeuerle, P. A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab Exp. Cell Res. 2011, 317 (9) 1255-60
22. Kipriyanov, S. M. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkins lymphoma J. Immunol. 2002, 169 (1) 137-44
23. Porter, D. L. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N. Engl. J. Med. 2011, 365 (8) 725-33
24. Kudo, K. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing Cancer Res. 2014, 74 (1) 93-103
25. Kochenderfer, J. N.; Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors Nat. Rev. Clin. Oncol. 2013, 10 (5) 267-76
26. Widdison, W. C. Semisynthetic maytansine analogues for the targeted treatment of cancer J. Med. Chem. 2006, 49 (14) 4392-408
27. Roguska, M. A. Humanization of murine monoclonal antibodies through variable domain resurfacing Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (3) 969-73
28. Chari, R. V. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy Adv. Drug Delivery Rev. 1998, 31 (1-2) 89-104
29. Lambert, J. M. Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 2013, 76 (2) 248-62
30. Verma, S. Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 2012, 367 (19) 1783-91
31. Al-Katib, A. M. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkins lymphoma Clin. Cancer Res. 2009, 15 (12) 4038-45
32. Younes, A. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma J. Clin. Oncol. 2012, 30 (22) 2776-82
33. Ribrag, V. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma Clin. Cancer Res. 2014, 20 (1) 213-20
34. Trneny, M. Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887) J. Clin. Oncol. (ASCO Annual Meeting) 2014, 32 (5S) 8506 Abstract
35. Kellogg, B. A. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage Bioconjugate Chem. 2011, 22 (4) 717-27
36. Erickson, H. K. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 2006, 66 (8) 4426-33
37. Erickson, H. K. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjugate Chem. 2010, 21 (1) 84-92
38. Kovtun, Y. V. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen Cancer Res. 2006, 66 (6) 3214-21
39. Schabel, F.; Griswold, D.; Laster, W.; Corbett, T.; Lloyd, H. Quantitative evaluation of anticancer agent activity in experimental animals Pharmacol. Ther. A 1977, 1 (4) 411-435
40. Bissery, M. C. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue Cancer Res. 1991, 51 (18) 4845-52
41. Sun, X. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism Bioconjugate Chem. 2011, 22 (4) 728-35
42. Xie, H. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice J. Pharmacol. Exp. Ther. 2004, 308 (3) 1073-82
43. Erickson, H. K. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates Mol. Cancer Ther. 2012, 11 (5) 1133-42
44. Blanc, V. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies Clin. Cancer Res. 2011, 17 (20) 6448-58
45. Lopus, M. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules Mol. Cancer Ther. 2010, 9 (10) 2689-99
46. Lewis Phillips, G. D. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 2008, 68 (22) 9280-90